Bio-Rad Laboratories (BIO-B) Change in Receivables (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Change in Receivables data on file, last reported at $614.1 million in Q1 2026.

• Change in Receivables for Q1 2026 came in at $614.1 million, down 4.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.6 billion (up 2.96% YoY), and the FY2025 annual result was $2.7 billion, up 4.05% from the prior year.
• Change in Receivables fell to $614.1 million in Q1 2026 per BIO-B's latest filing, from $697.7 million in the prior quarter.
• Over five years, Change in Receivables peaked at $717.4 million in Q4 2022 and troughed at $614.1 million in Q1 2026.
• A 5-year average of $659.2 million and a median of $655.5 million in 2024 frame the typical range for Change in Receivables.
• The sharpest annual moves came in 2022 and 2025: Change in Receivables dropped 10.72% in 2022, then grew 10.38% in 2025.
• A 5-year view of Change in Receivables shows it stood at $717.4 million in 2022, then declined by 5.68% to $676.7 million in 2023, then retreated by 6.59% to $632.1 million in 2024, then increased by 10.38% to $697.7 million in 2025, then slipped by 11.98% to $614.1 million in 2026.
• Business Quant data shows BIO-B's Change in Receivables at $614.1 million in Q1 2026, $697.7 million in Q4 2025, and $653.8 million in Q3 2025.